Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Olive oil compound may fight heart disease in early trial

NCT ID NCT07422051

Disease control Sponsor: Spanish National Research Council Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether erythrodiol, a natural compound in pomace olive oil, can reduce early signs of atherosclerosis (hardening of the arteries). Twenty-two healthy adults will eat high-fat meals with different doses of erythrodiol, then researchers will measure how their bodies process fats and whether it reduces inflammation. The goal is to see if this olive oil component could help prevent heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
erythrodiol (a compound in pomace olive oil)
What this could lead to
If it works, this could point toward a dietary approach to reduce early steps of atherosclerosis, potentially lowering heart disease risk.
What could go wrong
This is a very small, early-phase trial in healthy young adults, not patients. It only looks at short-term effects after a meal, so long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 22 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 40 years. * Male or female volunteers. * Healthy individuals with no diagnosed diseases. * Normal-weight participants with a Body Mass Index (BMI) between 18.5 and 24.9 kg/m². * Ability to provide voluntary informed consent. * Willingness to comply with all study procedures. * Availability to participate in the two-phase selection process, including initial screening and subsequent laboratory tests. Exclusion Criteria: * Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances. * Current use of any medication, except hormonal contraceptives. * Pregnant or breastfeeding women. * Participation in a clinical trial with an investigational product within the last 60 days, or current enrolment in a clinical trial. * Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease atherosclerosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis cardiovascular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto de la Grasa-CSIC

    Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.